---
title: A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy
  for relapsed/refractory B-cell non-Hodgkin lymphoma
date: '2025-01-15'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39813680/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20250116171027&v=2.18.0.post9+e462414
source: Blood
description: 'Prizloncabtagene autoleucel (prizlon-cel), a novel bispecific chimeric
  antigen receptor (CAR) T-cell, targets and eliminates CD19/CD20 positive tumor cells.
  This phase 1, open-label study investigated the safety and efficacy of prizlon-cel
  in patients with relapsed/refractory B-cell non-Hodgkin Lymphoma (r/r B-NHL). Patients
  with CD19 and/or CD20-positive r/r B-NHL received a 3-day lymphodepletion (cyclophosphamide:
  300 mg/m2/d; fludarabine: 30 mg/m2/d) followed by an intravenous dose ...'
disable_comments: true
---
Prizloncabtagene autoleucel (prizlon-cel), a novel bispecific chimeric antigen receptor (CAR) T-cell, targets and eliminates CD19/CD20 positive tumor cells. This phase 1, open-label study investigated the safety and efficacy of prizlon-cel in patients with relapsed/refractory B-cell non-Hodgkin Lymphoma (r/r B-NHL). Patients with CD19 and/or CD20-positive r/r B-NHL received a 3-day lymphodepletion (cyclophosphamide: 300 mg/m2/d; fludarabine: 30 mg/m2/d) followed by an intravenous dose ...